Serafim  Papadimitriou

Alexander E Berezin

Professor

biography

Dr. Alexander E. Berezin has received PhD in 1994 in the State Medical University of Zaporozhye (Ukraine). He is currently working as a Professor of Medicine in the State Medical University of Zaporozhye (Ukraine). As a Chief of Cardiology Unit of Internal Medicine Department, his research goals are fundamental study of biological markers, the implementation of visualization procedures and percutaneous cardiovascular interventions, the development of cardiovascular prevention and rehabilitation, especially in the field affected heart failure, atherosclerosis, and coronary artery disease. Based on this research and training in heart failure he has received several awards and honors, such as: Award of The Cabinet of Ministers of Ukraine (2002), Honor of The Ukrainian Cardiology Association (2004), and is serving one of the active members of the European Cardiology Society. He has authored more 550 research articles, 15 books/chapters. He is a fellow of the Ukrainian Cardiology Association; Member of the Ukrainian Heart Failure Association; Member of Heart Failure Association of the ESC; Member of European Acute Cardiovascular Care Association; Member of W.G. on Atherosclerosis and Vascular Biology of the ESC; Member of European Association of Percutaneous Cardiovascular Interventions; Member of European Association for Cardiovascular Prevention and Rehabilitation, Member of W.G. on Hypertension & the Heart of the ESC. He is current Editor-in-Chief of Biological Markers and Guided Therapy. He is serving as an editorial member of several reputed journals like Ukranian Medical J, J Cardiology and Therapy, Case Reports in Internal Medicine and expert Reviewers for journals like J Genetic Disorders and Genetic Reports; Obesity; Eur. J Clinical Investigations, etc

 

Area of Interest

Coronary artery disease
Heart Failure
Atherosclerosis Hypertension
Prognosis, Biological Markers
Genetic Markers
Comorbidities
Metabolic disorders
Visualization procedures
Cardiovascular Prevention and Rehabilitation
and Vascular Biology
Translation Medicine
Stem Cells


top publication

Alexander E Berezin: Biological markers of cardiovascular diseases. Part 6.Diagnostic and prognostic value of biological markers at risk stratification among patients with cardiorenal syndrome. LAMBERT Academic Publishing GmbH, Moskow, 2015. - 137 p. 05/2015; LAMBERT Academic Publishing GmbH., ISBN: 978-3-659-70941-8
Alexander E Berezin: Biological markers of cardiovascular diseases. Part 5.Diagnostic and prognostic value of biological markers at risk stratification among patients with pulmonary hypertension. LAMBERT Academic Publishing GmbH, Moskow, 2015. - 104 p.. 04/2015; LAMBERT Academic Publishing GmbH, Moskow., ISBN: 978-3-659-51904-8
Alexander E Berezin: Biological markers of cardiovascualr diseases. Part 4.Diagnostic and prognostic value of biological markers at risk stratification among patients with heart failure. LAMBERT Academic Publishing GmbH, Moskow, 2015. - 329 pp..03/2015; LAMBERT Academic Publishing GmbH.
Alexander E Berezin: Biological markers of cardiovascualr diseases. Part 3.Diagnostic and prognostic value of biological markers in stratification of patients with cardiometabolic risk. Lambert Academic Publishing GmbH, Moscow, 2015. - 300 p..02/2015; Academic Publishing LAMBERT GmbH.
Alexander E Berezin: Biological markers of cardiac suddenly death. Part 2.Clinical and predictive implication of biological markers at risk stratification of patients with fatal arrhythmias. Lambert Academic Publishing GmbH, Moscow. 2015. pp. 137.. 01/2015; Lambert Academic Publishing GmbH., ISBN: 978-3-659-67429-7
Alexander E Berezin: Biological markers of cardiovasculare diseases. Part 1.Clinical and predictive value of biological markers in risk stratification of patients with ischemic heart disease. Lambert Academic Publishing GMbH. Moscow, 2014; 368 pp..11/2014; Lambert Academic Publishing GMbH.
AlexanderEBerezin: Biological markers of metabolic syndrome. Kiev. 2012. - 252 pp.. 02/2012; Kiev., ISBN: 978-966-417-077-1
Alexander E Berezin: Berezin AE. Cardiometabolic risk.Definition, clinical value, biomarker identification. Kiev. 2012. - 257 pp.. 01/2012; Morion., ISBN: 978-966-417-077-1 Alexander E Berezin: Clinical lipidology. 12/2010; MORION: Kiev.
Book Chapters
Alexander E Berezin: Biomarker-Guided Therapy for Chronic Heart Failure. Biomarkers in Disease: Methods, Discoveries and Applications, edited by Victor R. Preedy and Vinood B. Patel. Springer, Switzerland, 2016.ISBN 978-94-007-7677-7. Biomarkers in Disease: Methods, Discoveries and Applications, 1st edited by Victor R. Preedy and Vinood B. Patel, 03/2016: chapter Biomarker-Guided Therapy for Chronic Heart Failure: pages 26; Springer, Switzerland.
Alexander E Berezin: Circulating vascular endothelial growth factor-1 in cardiovascular disease. Biomarkers in Disease: Methods, Discoveries and Applications, edited by Victor R. Preedy and Vinood B. Patel. Springer, Switzerland, 2016.ISBN 978-94-007-7677-7.
Biomarkers in Cardiovascular Disease, 1st edited by Victor R. Preedy, Vinood B. Patel, 01/2016: chapter Circulating vascular endothelial growth factor-1 in cardiovascular disease: pages 48; Springer., ISBN: 978-94-007-7677-7
Journal Publications
Alexander E. Berezin, Alexander A. Kremzer, Tatyana A Berezina, Yulia V. Martovitskaya, Elena A. Gromenko: Relation of osteoprotegerin level and numerous of circulating progenitor mononuclears in patients with metabolic syndrome. 03/2016; 3(2):501-513. DOI:10.7603/s40730-016-0007-7
Alexander E Berezin: Berezin AE. Is Global 2D-Strain Able to Be Better Tool for Cardiotoxicity Determination in Cancer Survivors Received Various Chemotherapeutic Agents? J Clin Trial Cardiol. 2016; 3(1): 1-6.
Alexander E Berezin: Berezin, A., Kremzer, A., Berezina, T., Martovitskaya, Y., & Gromenko, E. (2016). Relation of osteoprotegerin level and numerous of circulating progenitor mononuclears in patients with metabolic syndrome. Biomedical Research And Therapy, 3(2), 501-513.
Alexander E Berezin: Alexander E Berezin (2016), Prognostication of Cardiovascualr Complications in Metabolic Syndrome Patients: The Role of Vistafin. Diabetes Res Treat Open Access 3: 131-136.
Alexander E Berezin: Berezin AE, Kremzer AA, Predictive value of circulating osteonectin in patients with ischemic symptomatic chronic heart failure, Biomedical Journal (2016), 1-8 http://dx.doi.org/10.1016/j.bj.2015.08.002.
Alexander E Berezin: Berezin AE. Predictive value of vistafin in metabolic syndrome patients: focus on of cardiovascular complications. Biological Markers and Guided Therapy. 2016; 1 (3): 33 – 43.
Alexander E Berezin: Berezin A. The Biomarker Utility in Risk Stratification in an Ambulatory Heart Failure: ST2 or Galectin-3? Journal of Cardiology and Therapy 2016; 3(1): 456-458.
Alexander E Berezin: Berezin A. E. The Neutrophil Extracellular Traps: The Missed Link between Microvascular Inflammation and Diabetes? Metabolomics.2016; 6: 163-166. doi:10.4172/2153-0769.1000163. Metabolomics 01/2016; 6(1):163-166. DOI:10.4172/2153-0769.1000163
Alexander E Berezin: Alexander E. Berezin, Alexander A. Kremzer, Yulia V. Martovitskaya, Tatyana A. Berezina, Elena A. Gromenko. Pattern of endothelial progenitor cells and apoptotic endothelial cell-derived microparticles in chronic heart failure patients with preserved and reduced left ventricular ejection fraction. EBioMedicine. 2016; doi: 10.1016/j.ebiom.2016.01.018. EBioMedicine 01/2016; 4:86-94. DOI:10.1016/j.ebiom.2016.01.018
Alexander E Berezin: Berezin A (2016) The Rationality to Use of Galectin-3 as Target in Biomarker-Guided Therapy of Type 2 Diabetes Mellitus. Endocrinol Metab Syndr 5: 1000217. doi:10.4172/2161-1017.1000217.
Alexander E Berezin: Berezin AE. Is rationale to decrease serum osteoprotegerin and fetuin-A in type 2 diabetes mellitus patients? Diabetes & Metabolic Syndrome: Clinical Research & Reviews; 2016 [ahead of print]. Diabetes and Metabolic Syndrome Clinical Research and Reviews 01/2016;
Alexander Berezin: Is rationale to decrease serum osteoprotegerin and fetuin-A in type 2 diabetes mellitus patients?. Diabetes and Metabolic Syndrome Clinical Research and Reviews 01/2016; DOI:10.1016/j.dsx.2016.01.008
Alexander E Berezin: Berezin AE. Does Visfatin Predict Cardiovascular Complications in Metabolic Syndrome Patients? Endocrinol Metab Syndr. 2016; 5: 224-227. doi:10.4172/2161-1017.1000224.
Alexander E Berezin: Berezin AE (2016) Aortic Stenosis: Predictive Value of Cardiac Biomarkers in Older Patients. J Gerontol Geriatr Res 5: 263. doi:10.4172/2167-7182.1000263.
Alexander E Berezin: Berezin AE. Early Tumoricidal Drug-Induced Cardiotoxicity Determination: Possibilities of Biological Markers.Biological Markers and Guided Therapy, Vol. 2, 2015, no. 1, 143-151.
Alexander E. Berezin, Alexander A. Kremzer, Giovanni Cammarota, Anthony Zulli, Daniel Petrovic, Nieves Martell-Claros, Jan Sabo, Peter Kruzliak: Circulating endothelial-derived apoptotic microparticles and insulin resistance in non-diabetic patients with chronic heart failure.. Clinical Chemistry and Laboratory Medicine 12/2015
Alexander E Berezin: Berezin AE. The Biosensing of Microparticles: Benefits and Perspectives. ARC Journal of Diabetes and Endocrinology. 2015; 1(1): 31-34.
Alexander E Berezin, Alexander A Kremzer: Alexander E. Berezin, Alexander A. Kremzer (2015) Signature of circulating endothelial-derived progenitor cells in patients with metabolic syndrome and diabetes mellitus. Biological Markers and Guided Therapy, Vol. 2, no. 1, 113-135. http://dx.doi.org10.12988bmgt.2015.51211.
Gregoriy А. Igtatenko, Olga S. Nalotova, Alexander Е. Berezin: Gregoriy А. Ignatenko, Olga S. Nalotova, Alexander Е. Berezin. The fixed combination of aliskiren and nebivolol in hypertensive patients: the clinical perspectives. Biological Markers and Guided Therapy. 2015;. 2 (1): 107 - 111.
Alexander E Berezin: Berezin AE (2015) Cardiovascular Biomarkers in Routine Screening of Diabetic Patients. Clin Med Biochemistry Open Access 1: 107-112. doi:10.4172/cmbo.1000107.
Alexander E Berezin: Berezin AE. Predicting Heart Failure Phenotypes using Cardiac Biomarkers: Hype and Hope.JDisMarkers. 2015; 2(4): 1035-1041.
AlexanderEBerezin: Березин А.Е. Протеины внеклеточного матрикса как биомаркеры васкулярного ремоделирования и кардиоваскулярных клинических исходов. Укр. мед.часопис. 2015; 6 (110): 58-64.
Alexander E Berezin: Berezin A, Kremzer A, Berezina T, Martovitskaya Y, Gronenko O (2015) The Pattern of Circulating Microparticles in Diabetes Mellitus Patients with Known Subclinical Atherosclerosis. Clin Med Biochemistry Open Access 1: 104-110. doi:10.4172/cmbo.1000104.
Alexander E Berezin: Berezin AE. Prognostication of Early Cardio toxicity in Anti-Neoplastic Chemotherapy: The Role of Biological Markers. Heart Health Open Access; 2015; 2:116-120.. Open Access Journal of Contraception 11/2015; 2:116-120. DOI:10.14437/2378
Alexander E Berezin: Berezin AE. Can Fibroblast Growth Factor-23 Improve Prognostication in Heart Failure Patients? Austin J Cardiovasc Dis Atherosclerosis. 2015; 2(2): 1015-1016.
Alexander E Berezin: Berezin AE, Kremzer AA, Berezina TA, Martovitskaya Yu V. An association of insulin resistance with numerous of circulating microparticles originated from endothelial cells in cardiac failure individuals without history of diabetes mellitus. J Dis Markers. 2015; 2(4): 1032-1041.